Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12862232 | 1.00 | KDM4E (0.40) | KDM4EALDH1A1SMN1; SMN2HPGDKMT2A | |
| SCHEMBL1150820 | 0.86 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2HPGDKMT2A | |
| SCHEMBL12862231 | 0.86 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2HPGDKMT2A | |
| SCHEMBL1150834 | 0.84 | L3MBTL1 (0.43) | KDM4EALDH1A1SMN1; SMN2HPGDKMT2A | |
| SCHEMBL12875079 | 0.84 | KDM4E (0.36) | KDM4EALDH1A1SMN1; SMN2HPGDKMT2A | |
| SCHEMBL12862234 | 0.81 | KDM4E (0.40) | KDM4EALDH1A1SMN1; SMN2HPGDKMT2A | |
| SCHEMBL1150761 | 0.81 | KDM4E (0.40) | KDM4EALDH1A1SMN1; SMN2HPGDKMT2A | |
| SCHEMBL1150765 | 0.79 | ALDH1A1 (0.36) | KDM4EALDH1A1SMN1; SMN2HPGDKMT2A | |
| SCHEMBL12862284 | 0.78 | ALDH1A1 (0.38) | KDM4EALDH1A1SMN1; SMN2HPGDKMT2A | |
| SCHEMBL12874763 | 0.76 | KMT2A (0.36) | KDM4EALDH1A1SMN1; SMN2HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2291377-B1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | AVEXA LTD (AU) | 2015-02-18 | — | — | EP | disclosed |
| US-8431581-B2 | Imidazopyrimidines and uses thereof | AVEXA LIMITED (AU) | 2013-04-30 | — | — | US | disclosed |
| EP-2291377-A1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | Avexa Limited (AU) | 2011-03-09 | — | — | EP | disclosed |
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-02-03 | — | — | US | disclosed |
| WO-2010000031-A1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | TPMT, DPYD, IMPDH1 | KDM4E 1918/4885ALDH1A1 205/4885SMN1; SMN2 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.